Human Investing LLC Buys Shares of 1,000 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Human Investing LLC purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 1,000 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Van ECK Associates Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 18.4% during the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 273 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after buying an additional 294 shares during the period. Motley Fool Asset Management LLC boosted its position in Ultragenyx Pharmaceutical by 0.3% during the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock worth $8,005,000 after acquiring an additional 360 shares during the last quarter. KBC Group NV grew its stake in Ultragenyx Pharmaceutical by 24.5% in the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 506 shares during the period. Finally, M&T Bank Corp raised its holdings in Ultragenyx Pharmaceutical by 8.1% in the 3rd quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 525 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Down 2.4 %

Shares of RARE stock opened at $42.49 on Tuesday. The company has a market cap of $3.92 billion, a PE ratio of -6.57 and a beta of 0.60. The company’s fifty day simple moving average is $43.46 and its 200-day simple moving average is $49.59. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. JPMorgan Chase & Co. cut their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 22nd. Finally, Piper Sandler upped their price target on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $92.43.

Insider Buying and Selling

In related news, CEO Emil D. Kakkis sold 11,727 shares of the firm’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.